IMV News and Press, IMV Inc. From 05/29/20

IMV (NASDAQ: IMV ) jumps 9.4%  in premarket trading after results from its Phase 2 study of DPX-Survivac immunotherapy in advanced recurrent ovarian cancer showed prolonged durable clinical responses alongside favorable tolerability. More news on: IMV Inc., Healthcare stocks news, St...

Survivin-targeted T cell therapy continues to show significant, durable anti-tumor activity and is well-tolerated in this hard-to-treat cancer patient population 5/19 patients (26%) achieved a partial regression on target lesions Strong translational data link the observed cl...

CleanSpark (NASDAQ: CLSK ) +38% . More news on: CleanSpark, Inc., Aurora Cannabis Inc., IMV Inc., Stocks on the move, , , Read more ...

IMV (NASDAQ: IMV ) is up  17%  premarket after announcing positive preclinical results demonstrating robust immunogenic and antibody responses from the majority of peptide epitopes. More news on: IMV Inc., Healthcare stocks news, Stocks on the move, Read more ...

Majority of 23 peptide epitopes selected by IMV demonstrated robust antibody responses in an animal model after first and second dose in DPX formulation without any additional adjuvant DPX-COVID-19 to utilize multi-target approach, to optimize immune response against virus’ weak...

Gainers: Oasis Midstream Partners (NASDAQ: OMP ) +79% . More news on: Oasis Midstream Partners LP, Aurora Cannabis Inc., Marine Petroleum Trust, Stocks on the move, , Read more ...

Sorrento Therapeutics (NASDAQ: SRNE ) +36%  in reaction to  reports  that it has discovered an antibody, dubbed STI-1499, that, it says, can provide 100% inhibition of COVID-19. More news on: Sorrento Therapeutics, Inc., Moderna, Inc., Fulgent Genetics, Inc., Stocks on the ...

IMV Inc. (IMV) Q1 2020 Results Earnings Conference Call May 15, 2020, 08:00 AM ET Company Participants Pierre Labbé - Chief Financial Officer Frederic Ors - Chief Executive Officer Joanne Schindler - Chief Medical Officer Marianne Stanford - Vice President, Research and De...

IMV (NASDAQ: IMV ): Q1 GAAP EPS of -C$0.19 misses by C$0.04 . More news on: IMV Inc., Earnings news and commentary, , Read more ...

Phase 2 SPiReL study of DPX-Survivac combination regimen with Keytruda® in r/r DLBCL successfully reached primary efficacy endpoint with 64% (7/11) of evaluable patients demonstrating a clinical response Translational and updated clinical response data from Phase 2 DeCidE1 st...